All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000506-52 | Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study | 2009-06-02 | due-trials |
| Reported results | 2004-000696-34 | A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a plati... | 2005-10-17 | due-trials |
| Reported results | 2004-002437-39 | A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuous ... | 2006-10-24 | due-trials |
| Completed, but no date, and reported results | 2004-003195-11 | The effect of the co-administration of multiple oral doses of the fructose-1,6-bisphosphatase (FBPase) inhibitor CS-917 and glibenclamide on pharmacokinetics, safety and tolerability in diabetic patie... | bad-data | |
| Reported results | 2004-004415-29 | A Phase IIa, multi-center, multi-national, open-label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patients ... | 2005-10-19 | due-trials |
| Reported results | 2005-000447-28 | EFFICACY AND SAFETY OF AMLODIPINE USED AS ADD-ON THERAPY IN MODERATELY TO SEVERELY HYPERTENSIVE PATIENTS NOT ADEQUATELY CONTROLLED BY OLMESARTAN MEDOXOMIL 20 MG MONOTHERAPY | 2006-12-22 | due-trials |
| Reported results | 2005-000450-75 | Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg Alone | 2007-05-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2005-003511-75 | Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients with Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins... | 2007-12-18 | bad-data |
| Reported results | 2005-004659-36 | Treat-to-target study of olmesartan medoxomil and an add-on treatment algorithm consisting of hydrochlorothiazide and amlodipine besylate in patients with mild to moderate hypertension | 2008-04-08 | due-trials |
| Reported results | 2006-000758-29 | A PHASE IIB, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE-DUMMY, MULTI-CENTER, MULTI NATIONAL, MULTI-DOSE STUDY OF DU-176b COMPARED TO DALTEPARIN IN PATIENTS UNDERGOING ELECTIVE UNILATERAL TOTAL H... | 2007-06-09 | due-trials |
| Reported results | 2006-003876-37 | Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy | 2008-03-30 | due-trials |
| Reported results | 2006-003877-28 | Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg versus 40/25 mg in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 4... | 2008-10-03 | due-trials |
| Reported results | 2006-005047-28 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS | 2009-02-12 | due-trials |
| Reported results | 2007-001271-11 | A PHASE 2, RANDOMIZED, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF SAFETY OF FOUR FIXED DOSE REGIMENS OF DU-176b IN SUBJECTS WITH NON-VALVULAR ATRIAL FIBRILLATION | 2008-08-19 | due-trials |
| Reported results | 2007-003060-22 | A 24-WEEK MULTICENTRE, RANDOMISED, DOUBLE BLIND, CONTROLLED, PARALLEL GROUP NON-INFERIORITY STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL VERSUS CANDESARTAN CILEXETIL IN PATIENTS WIT... | 2009-08-12 | due-trials |
| Reported results | 2007-003130-41 | Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients with Metabolic Syndrome | 2010-12-02 | due-trials |
| Reported results | 2007-003131-23 | Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects with Metabolic Syndrome | 2011-08-08 | due-trials |
| Completed, but no date, and reported results | 2007-004574-11 | RANDOMISED, DOUBLE-BLINDED, PLACEBO- CONTROLLED PHASE 2 STUDY OF CS-1008 IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN CHEMOTHERAPY NAÏVE SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG ... | bad-data | |
| Reported results Terminated | 2007-005263-97 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS | 2008-04-23 | due-trials |
| Reported results | 2007-005675-34 | A PHASE 2 OPEN-LABEL RANDOMISED, TRIAL OF CS-1008 IN COMBINATION WITH IRINOTECAN VS IRINOTECAN ALONE IN SUBJECTS WITH METASTATIC COLORECTAL CARCINOMA WHO FAILED FIRST LINE OXALIPLATIN BASED CHEMOTHERA... | 2011-05-30 | due-trials |
| Reported results | 2008-003534-25 | A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CO ADMINISTRATION OF TRIPLE COMBINATIONS OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, AND HYDROCHLOROTHIAZIDE CO... | 2011-01-04 | due-trials |
| Reported results | 2008-003535-20 | A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBI... | 2010-09-07 | due-trials |
| Reported results | 2008-004522-16 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLAT... | 2013-06-24 | due-trials |
| Reported results Terminated | 2008-005848-16 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS 7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY | 2012-05-31 | due-trials |
| Reported results | 2009-012966-30 | Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION | 2012-11-05 | due-trials |
| Reported results | 2009-013342-92 | EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM) | 2011-09-30 | due-trials |
| Reported results | 2009-014290-40 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP,MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS (LMW) | 2013-04-30 | due-trials |
| Reported results | 2009-015400-26 | MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS | 2011-12-01 | due-trials |
| Reported results | 2009-016025-34 | A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 1/2 STUDY OF ARQ 197 IN COMBINATION WITH IRINOTECAN AND CETUXIMAB IN SUBJECTS WITH METASTATIC COLORECTAL CANCER WITH WILD-TYPE KRAS WHO HAVE RECEIVED FRONT-LINE... | 2014-12-16 | due-trials |
| Reported results | 2009-016083-36 | Phase 2 Study of CS-7017 and Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy | 2013-04-23 | due-trials |
| Reported results | 2010-021082-74 | RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO H... | 2013-12-06 | due-trials |
| Reported results | 2010-022365-10 | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous... | 2016-10-06 | due-trials |
| Reported results | 2011-004064-29 | A PHARMACODYNAMIC EVALUATION OF SWITCHING FROM TICAGRELOR TO PRASUGREL IN SUBJECTS WITH STABLE CORONARY ARTERY DISEASE: 2ND SWITCHING ANTIPLATELET AGENTS (SWAP 2) | 2013-02-13 | due-trials |
| Reported results | 2012-003009-88 | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-CENTER STUDY OF ADDING EDOXABAN OR CLOPIDOGREL TO ASPIRIN TO MAINTAIN PATENCY IN SUBJECTS WITH PERIPHERAL ARTERIAL DISEASE FOLLOWING FEMOROPOPLITEAL END... | 2014-12-03 | due-trials |
| Reported results | 2012-003308-10 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY | 2017-03-02 | due-trials |
| Reported results | 2012-004373-80 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord ... | 2015-03-21 | due-trials |
| Reported results | 2013-000104-42 | Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension | 2014-04-09 | due-trials |
| Reported results | 2013-003148-21 | A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing ... | 2016-02-04 | due-trials |
| Reported results | 2013-004371-12 | Phase 3, Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-type Subjects with Locally Advanced or Metastatic... | 2016-11-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-004890-28 | A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After Fir... | 2020-09-08 | bad-data |
| Reported results | 2013-005161-40 | A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia | 2016-08-19 | due-trials |
| Reported results | 2013-005162-20 | A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia | 2017-01-12 | due-trials |
| Reported results | 2013-005163-10 | A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia | 2016-07-07 | due-trials |
| Reported results | 2013-005164-26 | An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia | 2017-04-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-000148-14 | A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN | 2021-04-30 | bad-data |
| Reported results | 2014-003972-21 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SAFETY STUDY OF DS-5565 FOR TREATMENT OF PAIN DUE TO FIBROMYALGIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE | 2017-07-06 | due-trials |
| Reported results | 2014-004708-30 | A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH ... | 2017-09-15 | due-trials |
| Reported results | 2015-001824-43 | A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, phar... | 2019-08-13 | due-trials |
| Reported results | 2015-002222-40 | Randomized, Placebo-Controlled, Double Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum Based Therapy in First Line Setting in Subjects with Recurrent or Metasta... | 2018-02-21 | due-trials |
| Trial is outside EEC, and reported results | 2015-003005-41 | A Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of a Compounded 4 mg/mL Olmesartan Medoxomil Suspension (Total Dose 40 mg) and 40 mg Olmesartan Medoxomil Tablets (Benicar... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003328-30 | An Open-Label Study of the Single-Dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension | bad-data | |
| Trial is outside EEC, and reported results | 2015-003329-32 | Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-004856-24 | A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to ... | 2023-07-12 | bad-data |
| Reported results | 2015-005211-32 | A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to Sta... | 2019-08-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-005732-18 | A Phase 1, Open-Label, Single-dose, Non-randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients Estudio en fase I, en abierto, de dosis única y no rando... | 2021-09-16 | bad-data |
| Completed, but no date, and reported results | 2016-000978-38 | Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Respiratory Tract Infections in adults with risk of recurrence after standard t... | bad-data | |
| Ongoing, reported early | 2016-000979-24 | Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after st... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000991-49 | A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF ... | 2022-05-24 | bad-data |
| Reported results | 2016-001795-30 | Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance | 2018-10-26 | due-trials |
| Reported results | 2016-002683-14 | Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent plac... | 2019-06-06 | due-trials |
| Ongoing | 2016-002919-18 | A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and ... | not-yet-due | |
| Reported results | 2016-003069-25 | A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation ... | 2018-09-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003930-26 | Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation ¿ In Atrial Fibrillation. ENVISAGE TAVI-AF Edoxaban ris... | 2021-03-03 | bad-data |
| Ongoing, reported early | 2016-004986-18 | A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refractor... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-000475-90 | AN OPEN-LABEL, RANDOMISED, PARALLEL-GROUP, MULTICENTRE, OBSERVATIONAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF EDOXABAN TOSYLATE IN CHILDREN FROM 38 WEEKS GESTATIONAL AGE TO LESS THAN 18 YEARS OF AGE ... | 2021-12-03 | bad-data |
| Completed, but no date, and reported results Terminated | 2017-000552-25 | Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE) | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2017-003466-28 | A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201A IN SUBJECTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER [DESTINY-CRC01] | 2020-11-10 | bad-data |
| Ongoing, reported early | 2017-004781-94 | A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastati... | not-yet-due | |
| Ongoing, reported early | 2018-000221-31 | A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and... | not-yet-due | |
| Other | 2018-000222-61 | A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/... | not-yet-due | |
| Ongoing, reported early | 2018-003069-33 | A phase 3, multicenter, randomized, open-label, active-controlled trial of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician’s choice for HER... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-001512-34 | A PHASE 2, OPEN-LABEL, SINGLE-ARM TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HER2-POSITIVE, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PR... | 2024-02-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-004418-32 | A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC) | 2022-02-03 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-000192-20 | A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib | 2023-07-07 | bad-data |
| Ongoing | 2020-000730-17 | HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (N... | not-yet-due | |
| Ongoing | 2020-002774-27 | Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations and Progressed on or After Applicable Targeted Therapy and P... | not-yet-due | |
| Ongoing | 2020-003427-42 | A Phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC) [DESTINY-Lung02] | not-yet-due | |
| Ongoing | 2020-003982-20 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast C... | not-yet-due | |
| Ongoing | 2020-004559-34 | A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarc... | not-yet-due | |
| Ongoing | 2020-004643-80 | Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer with or without Actionable Genomic Alterations | not-yet-due | |
| Ongoing, reported early | 2020-004782-39 | A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02) | not-yet-due | |
| Ongoing | 2020-004954-31 | Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma | not-yet-due | |
| Ongoing | 2021-002555-10 | A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS =50%) Non-small Cell Lung Cancer W... | not-yet-due | |
| Ongoing | 2021-005879-40 | A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lu... | not-yet-due | |
| Ongoing | 2022-000503-13 | A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) Estudio de fase... | not-yet-due | |
| Completed, report not yet due | 2022-000676-19 | A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals with Pseudoxanthoma Elasticum | 2023-11-21 | not-yet-due |